ALKS Q2 2024 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$399M-35.4% YoY

Gross Profit

$338M84.6% margin

Operating Income

$110M27.5% margin

Net Income

$91M22.9% margin

EPS (Diluted)

$0.53

QoQ Revenue Growth

+13.9%

Cash Flow

Operating Cash Flow

$146M

Free Cash Flow

$139M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$923M

Stockholders' Equity

$1.3B

Cash & Equivalents

$535M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$399M	$617M	-35.4%
Gross Profit	$338M	$554M	-39.1%
Operating Income	$110M	$281M	-60.9%
Net Income	$91M	$237M	-61.5%

Revenue Segments

Product

$269M50%

Vivitrol

$112M21%

Aristada And Aristada Initio

$86M16%

L Y B A L V I

$71M13%